PROBIOMED launches a new drug to treat erectile dysfunction without modifying lifestyle.
In Mexico, one in two men over 40 years has a mild form of erectile dysfunction; however, as age advances, the sever form of this condition becomes more common.
Mexico City, June, 2015.- In the framework of the celebration of its 45 years in the
Mexican market, PROBIOMED presents a new medication for the treatment of
erectile dysfunction in adult men over 18 years. The molecule, called Lodenafilo,
was approved by the Federal Commission for Protection against Health Risks
(COFEPRIS) in June 2014, as a medication for the treatment of erectile
dysfunction.
This drug has the necessary clinical studies to demonstrate its safety and efficacy,
including Phase III studies. It is a Brazilian patent innovation medicine that, since
its launch in that market 7 years ago, has positioned itself in the first places of sale.
This is due to the fact that it has a high cardiovascular safety profile and a high
degree of tolerance, in addition to its proven results in the latino population.
“We are sure that this product will support the therapeutic portfolio of doctors in the
treatment of erectile dysfunction, since it has competitive advantages in the market
of drugs indicated for this condition; and to the patients, who will be able to count
on a high quality and affordable product” says Carlos Domínguez, Commercial
Director of PROBIOMED. Among the characteristics of the treatment, the fact that
it does not affect patients´ lifestyle is emphasized, since it can be taken in fasting
or with food. Moreover, fatty foods and alcohol do not reduce neither drug
absorption nor effectiveness, unlike others.
In Mexico, one in two men over 40 years has a mild form of erectile dysfunction;
however, as age advances, the severe form of this condition becomes more
common. According to the Mexican Society of Urology, in addition to age, chronic
pathologies such as diabetes mellitus, arterial hypertension, peptic ulcer and
prostate and cardiovascular diseases are among the most well-known risk factors
for this disorder.
This medication allows successful sexual encounters without restrictions on
lifestyle. It offers excellent cardiovascular safety, since it does not generate
alterations in heart rhythm (arrhythmias), regardless of whether alcohol is
consumed or not. Its action can last up to 6 hours and does not increase sexual
desire or cause erections without sexual stimulation.
PROBIOMED S.A. of C.V. is a Mexican company focused on research,
development, manufacturing and marketing of biotechnology and pharmaceutical
products for human health. Since its foundation, more than 40 years ago,
PROBIOMED has contributed with effective solutions to face the continuous
challenges that health demands. PROBIOMED is a high-tech organization with the
highest added value in the industry. It has a broad portfolio of both pharmaceutical
and recombinant proteins, covering various medical specialties such as Family
Medicine, Internal Medicine, Endocrinology, Cardiology, Neurology, Psychiatry,
Otolaryngology, Gynecology, Traumatology, Nephrology, Oncology and
Hematology, mainly.
